Literature DB >> 20592077

Dendritic cells loaded with tumor B cells elicit broad immunity against murine gammaherpesvirus 68 but fail to prevent long-term latency.

Janet Weslow-Schmidt1, Fang Ye, Stephanie S Cush, Kathleen A Stuller, Marcia A Blackman, Emilio Flaño.   

Abstract

It is still unknown whether a noninfectious gammaherpesvirus vaccine is able to prevent or reduce virus persistence. This led us to use dendritic cells loaded with tumor B cells as a vaccine approach for the murine gammaherpesvirus 68 (gammaHV68) model of infection. Dendritic cells loaded with UV-irradiated latently infected tumor B cells induce broad, strong, and long-lasting immunity against gammaHV68. Dendritic cell vaccination prevents the enlargement of lymph nodes and severely limits acute infection and early latency but does not prevent gammaHV68 from establishing long-term latency. Our findings support the concept that attenuated viruses may be the best vaccine option for preventing gammaherpesvirus persistence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592077      PMCID: PMC2918994          DOI: 10.1128/JVI.00571-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Cross-presentation, dendritic cells, tolerance and immunity.

Authors:  W R Heath; F R Carbone
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Analysis of virus-specific CD4(+) t cells during long-term gammaherpesvirus infection.

Authors:  E Flaño; D L Woodland; M A Blackman; P C Doherty
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

4.  Latent antigen vaccination in a model gammaherpesvirus infection.

Authors:  E J Usherwood; K A Ward; M A Blackman; J P Stewart; D L Woodland
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 5.  Immunotherapeutic strategies for EBV-associated malignancies.

Authors:  R Khanna; J Tellam; J Duraiswamy; L Cooper
Journal:  Trends Mol Med       Date:  2001-06       Impact factor: 11.951

6.  Murine gamma-herpesvirus-68: a mouse model for infectious mononucleosis?

Authors:  M A Blackman; E Flaño; E Usherwood; D L Woodland
Journal:  Mol Med Today       Date:  2000-12

Review 7.  Dissecting the host response to a gamma-herpesvirus.

Authors:  P C Doherty; J P Christensen; G T Belz; P G Stevenson; M Y Sangster
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice.

Authors:  L Liu; E J Usherwood; M A Blackman; D L Woodland
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Antibody-mediated control of persistent gamma-herpesvirus infection.

Authors:  In-Jeong Kim; Emilio Flaño; David L Woodland; Marcia A Blackman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

10.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.